Parkinson's sleep study halted early – what we know

NCT ID NCT03968744

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether the drug safinamide (Xadago) could improve sleep quality in people with Parkinson's disease. Eleven participants took safinamide for 12 weeks while their sleep was measured. The trial was terminated early, so the results are not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

safinamide (Xadago)

What this could lead to

If it works, this could point toward a treatment for sleep problems in Parkinson's disease.

What could go wrong

The trial was terminated early and had only 11 participants, so results are very limited. It is unclear if safinamide truly helps sleep.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PARKINSON'S DISEASE (AT LATER STAGE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Neurocenter of Southern Switzerland - Ente Ospedaliero Cantonale (EOC)

    Lugano, 6900, Switzerland